Full Breakdown
Johnson & Johnson's Erleada Shows Promise in Reducing Progression and Death in High-Risk Prostate Cancer
5/31/2026, 8:10:58 PM
Study Findings Reveal Significant Benefits
Johnson & Johnson reported that adding Erleada (apalutamide) to standard hormone therapy before and after prostatectomy improved outcomes for men with high-risk localized or locally advanced prostate cancer. The phase-III trial, presented at the ASCO meeting in Chicago on May 31, 2026, enrolled >2,000 patients and followed them >5 years. At surgery, 8.9 % of the combination group had little or no detectable cancer versus 1 % with hormone alone—a nine-fold increase. The regimen cut the risk of metastasis or death by 20 % and lowered recurrence-related death by 29 % for those treated a full year. Median time to subsequent therapy extended to >6 years, about double the hormone-only arm.
Key Data Summary
- >2,000 high-risk patients enrolled; follow-up >5 years.
- Pathologic complete response: 8.9 % with Erleada + hormone vs 1 % with hormone alone.
- Metastasis or death risk down 20 %; recurrence death down 29 % with full-year therapy.
- Median time to additional treatment >6 years vs ?3 years with hormone alone.
Key Figures & Groups
The trial was led by Dr. Mary-Ellen Taplin of the Dana-Farber Cancer Institute, Boston. Mark Wildgust, J&J’s medical-affairs lead for oncology, presented the company’s perspective at the ASCO meeting in Chicago.
Background & Context
Standard care for high-risk prostate cancer in the U.S. relies on prostatectomy or radiation, with nearly half of patients experiencing recurrence. About 40 % of the 330,000 annual U.S. prostate-cancer diagnoses are high-risk. Erleada, approved in 2018 for metastatic disease, is the first ARPI evaluated for localized high-risk disease.
Why It Matters
If confirmed, the regimen could reshape guidelines by offering a curative-intent option that reduces reliance on salvage therapy, potentially lowering costs and improving quality of life for a large patient group.
Official Statements & Responses
Dr. Mary-Ellen Taplin called the results “paradigm-changing,” noting no ARPIs are approved for this stage. Mark Wildgust described the benefit “unequivocal” and said the evidence shows Erleada adds a previously unseen effect. Johnson & Johnson said the safety profile matches earlier studies, with hot flushes, urinary incontinence and erectile dysfunction as common side effects, and announced plans to seek global approval for the earlier-stage indication.
Verbatim Quotes
- “No ARPIs are approved for localized high-risk prostate cancer with either surgery or radiation. So the (data) would be paradigm changing,” — Dr. Mary-Ellen Taplin, Dana-Farber Cancer Institute
- “The patient benefit here is unequivocal,” — Mark Wildgust, Johnson & Johnson, Medical Affairs Lead for Oncology
- “I think that the evidence is really showing that Erleada is adding something that we had not seen before.” — Mark Wildgust, Johnson & Johnson, Medical Affairs Lead for Oncology
What’s Next
Johnson & Johnson will file supplemental applications with the U.S. FDA and other regulators to add high-risk localized disease to Erleada’s label, while continued follow-up will track long-term survival and safety.
